CMS Innovation Center Exploring ‘Array’ Of Cost-Lowering Medicare Payment Models

CMMI payment demonstrations are viewed as way of skirting statutory obstacles to experimenting with new approaches to reimbursement and could lead to significant drug pricing reforms if legislative efforts fail. However, HHS is not signaling an intent to pursue transformational new models at this point.

Drug costs_1B_546120055_1200.jpg
• Source: Shutterstock

More from Pricing Debate

More from Market Access